ClinicalTrials.gg
CompletedNCT01581931Updated Aug 20, 2013Results posted

Bioequivalence of Metformin Under Fed Conditions After Administration of Linagliptin / Metformin Fixed Dose Combination Tablet and Single Tablets

A Phase 1 interventional study of Linagliptin/metformin and Metformin in Healthy, sponsored by Boehringer Ingelheim. Completed at 1 site in Germany. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2013-08-20.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

To establish bioequivalence (BE) under fed conditions between metformin in linagliptin/metformin fixed dose combination tablet and metformin reference product administered in free combination togther with linagliptin

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.

Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy male and female subjects

Exclusion criteria

Exclusion criteria:

  1. Any relevant deviation from healthy conditions
05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    Linagliptin/metformin

    fixed dose combination tablet (FDC)

    Drug: Linagliptin/metformin

  • Experimental
    Linagliptin and metformin

    single tablets

    Drug: Metformin · Drug: Linagliptin

Interventions

06

What researchers measure

Primary outcomes

  1. Area Under Curve From 0 to tz Hours (AUC0-tz) of Metformin

    AUC0-tz represents the area under the concentration curve of metformin in plasma from 0 to the time of the last quantifiable plasma contentration of the analyte. Note, the geometric mean is actually an adjusted geometric mean.

    Time frame: 0:20, 0:40, 1, 1:30, 2, 3, 4, 5, 6, 8, 12, 24, 34, 48, 72 hours

  2. Maximum Concentration (Cmax) of Metformin

    Cmax represents the maximum concentration of metformin in plasma. Note, the geometric mean is actually an adjusted geometric mean.

    Time frame: 0:20, 0:40, 1, 1:30, 2, 3, 4, 5, 6, 8, 12, 24, 34, 48, 72 hours

Secondary outcomes

  1. Area Under Curve From 0 to Infinity Hours (AUC0-infty) of Metformin

    AUC0-infty represents the area under the concentration curve of metformin in plasma from time 0 extrapolated to infinity. Note, the geometric mean is actually an adjusted geometric mean.

    Time frame: 0:20, 0:40, 1, 1:30, 2, 3, 4, 5, 6, 8, 12, 24, 34, 48, 72 hours

  2. Time to Maximum Concentration (Tmax) of Metformin

    Time from dosing to the maximum concentration of metformin in plasma.

    Time frame: 0:20, 0:40, 1, 1:30, 2, 3, 4, 5, 6, 8, 12, 24, 34, 48, 72 hours

  3. Terminal Half-life t1/2 of Metformin

    The terminal half-life of metformin in plasma is denoted by t1/2.

    Time frame: 0:20, 0:40, 1, 1:30, 2, 3, 4, 5, 6, 8, 12, 24, 34, 48, 72 hours

07

Results

Posted Aug 20, 2013

Participant flow

First Period
Participant flow — First Period
MilestoneLina+Met Single Tablets / Lina+Met FDC TabletLina+Met FDC Tablet / Lina+Met Single Tablets
Started1616
Completed1616
Not completed00
Washout
Participant flow — Washout
MilestoneLina+Met Single Tablets / Lina+Met FDC TabletLina+Met FDC Tablet / Lina+Met Single Tablets
Started1616
Completed1615
Not completed01
Withdrew: Adverse event01
Second Period
Participant flow — Second Period
MilestoneLina+Met Single Tablets / Lina+Met FDC TabletLina+Met FDC Tablet / Lina+Met Single Tablets
Started1615
Completed1615
Not completed00

Outcome measures

SecondaryArea Under Curve From 0 to Infinity Hours (AUC0-infty) of Metformin

AUC0-infty represents the area under the concentration curve of metformin in plasma from time 0 extrapolated to infinity. Note, the geometric mean is actually an adjusted geometric mean.

Time frame:
0:20, 0:40, 1, 1:30, 2, 3, 4, 5, 6, 8, 12, 24, 34, 48, 72 hours
Reported as:
Geometric mean · ng·h/mL
Area Under Curve From 0 to Infinity Hours (AUC0-infty) of Metformin
ng·h/mLLina+Met Single TabletsLina+Met FDC Tablet
Area Under Curve From 0 to Infinity Hours (AUC0-infty) of Metformin7343.59 ± 9.77174.30 ± 9.7
Statistical analysis
  • Lina+Met Single Tablets vs Lina+Met FDC Tablet · ANOVA · Adjusted geometric mean ratio: 97.69 · 95% CI 93.63 to 101.94Numerator: FDC tablet; denominator: single tablets of linagliptin and metformin; The dispersion parameter is actually the geometric coefficient of variation.
SecondaryTime to Maximum Concentration (Tmax) of Metformin

Time from dosing to the maximum concentration of metformin in plasma.

Time frame:
0:20, 0:40, 1, 1:30, 2, 3, 4, 5, 6, 8, 12, 24, 34, 48, 72 hours
Reported as:
Median · Hours
Time to Maximum Concentration (Tmax) of Metformin
HoursLina+Met Single TabletsLina+Met FDC Tablet
Time to Maximum Concentration (Tmax) of Metformin4.00 (2.00 to 6.00)4.00 (1.00 to 6.00)
SecondaryTerminal Half-life t1/2 of Metformin

The terminal half-life of metformin in plasma is denoted by t1/2.

Time frame:
0:20, 0:40, 1, 1:30, 2, 3, 4, 5, 6, 8, 12, 24, 34, 48, 72 hours
Reported as:
Geometric mean · Hours
Terminal Half-life t1/2 of Metformin
HoursLina+Met Single TabletsLina+Met FDC Tablet
Terminal Half-life t1/2 of Metformin9.14 ± 87.48.03 ± 86.0
PrimaryArea Under Curve From 0 to tz Hours (AUC0-tz) of Metformin

AUC0-tz represents the area under the concentration curve of metformin in plasma from 0 to the time of the last quantifiable plasma contentration of the analyte. Note, the geometric mean is actually an adjusted geometric mean.

Time frame:
0:20, 0:40, 1, 1:30, 2, 3, 4, 5, 6, 8, 12, 24, 34, 48, 72 hours
Reported as:
Geometric mean · ng·h/mL
Area Under Curve From 0 to tz Hours (AUC0-tz) of Metformin
ng·h/mLLina+Met Single TabletsLina+Met FDC Tablet
Area Under Curve From 0 to tz Hours (AUC0-tz) of Metformin7219.03 ± 9.87057.52 ± 9.8
Statistical analysis
  • Lina+Met Single Tablets vs Lina+Met FDC Tablet · ANOVA · Adjusted geometric mean ratio: 97.76 · 90% CI 93.64 to 102.07Numerator: FDC tablet; denominator: single tablets of linagliptin and metformin; The dispersion parameter is actually the geometric coefficient of variation.
PrimaryMaximum Concentration (Cmax) of Metformin

Cmax represents the maximum concentration of metformin in plasma. Note, the geometric mean is actually an adjusted geometric mean.

Time frame:
0:20, 0:40, 1, 1:30, 2, 3, 4, 5, 6, 8, 12, 24, 34, 48, 72 hours
Reported as:
Geometric mean · ng/mL
Maximum Concentration (Cmax) of Metformin
ng/mLLina+Met Single TabletsLina+Met FDC Tablet
Maximum Concentration (Cmax) of Metformin855.09 ± 10.0844.72 ± 10.0
Statistical analysis
  • Lina+Met Single Tablets vs Lina+Met FDC Tablet · ANOVA · Adjusted geometric mean ratio: 98.79 · 90% CI 94.55 to 103.21Numerator: FDC tablet; denominator: single tablets of linagliptin and metformin; The dispersion parameter is actually the geometric coefficient of variation.

Adverse events

Collected over First treatment with study drug until End-of-Study (which was within 4 to 14 days after last study drug administration), i.e., 39 to 49 days after first treatment with study drug.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Lina+Met Single Tablets—0/31 (0%)6/31 (19.4%)
Lina+Met FDC Tablet—1/32 (3.1%)9/32 (28.1%)
Most frequent serious events
Most frequent serious events
EventLina+Met Single TabletsLina+Met FDC Tablet
Clavicle fractureInjury, poisoning and procedural complications0/311/32
Road traffic accidentInjury, poisoning and procedural complications0/311/32
Most frequent other events
Most frequent other events
EventLina+Met Single TabletsLina+Met FDC Tablet
HeadacheNervous system disorders5/315/32
NauseaGastrointestinal disorders2/312/32
VomitingGastrointestinal disorders2/310/32
NasopharyngitisInfections and infestations0/312/32
DiarrhoeaGastrointestinal disorders1/312/32

Baseline characteristics

Age Continuous
Age Continuous(years)Overall Study
Mean38.8 ± 9.9
Sex: Female, Male
Sex: Female, Male(Participants)Overall Study
Female17
Male15
08

Study locations

1 site
  • 1288.20.1 Boehringer Ingelheim Investigational Site
    Biberach, Germany
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2012, a primary completion of Jun 2012 and a completion of Jun 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2013, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 19, 2012
First posted
Apr 20, 2012
Start
Apr 2012
Primary completionActual
Jun 2012
CompletionActual
Jun 2012
Results first posted
Aug 20, 2013
Last update
Aug 20, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 20, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01581931
Responsible party
Sponsor
First posted
Apr 20, 2012
Start date
Apr 2012
Primary completion
Jun 2012
Completion
Jun 2012
Results posted
Aug 20, 2013
Last update
Aug 20, 2013

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Linagliptin · Metformin

Start the discussion